How to Value a Family Medicine Practice in 2026

Family medicine is the workhorse of American primary care, and it's also the specialty where I see the widest valuation gap between what sellers expect and what buyers actually pay. A family doc calls me and says "my practice does $1.6M a year, it must be worth $1.5M, right?" Then we look at the EBITDA, the payer mix, and the buyer pool, and the realistic number comes in at $600-$900K. That conversation is awkward but necessary.

Here's how family medicine valuation actually works in 2026, what separates a 3x practice from a 5x practice, and why the rural family doc in Nebraska often ends up with better exit economics than her suburban Dallas colleague.

The 3-5x EBITDA Range

Family medicine practices in 2026 sell in a 3-5x EBITDA range, with most transactions clustering at 3.5-4.5x. The range is tighter than internal medicine because family practices see a broader age mix — the senior-heavy Medicare Advantage economics that push internal medicine valuations to 6x simply don't apply the same way when 40% of your panel is pediatric and commercial.

On a practice generating $250K in adjusted EBITDA after normalizing owner compensation to $240K (roughly what a health system would pay for your slot as an employed physician), you're looking at $875K-$1.25M in enterprise value. Smaller solo practices with thinner margins trade closer to SDE-based multiples of 2-3x, which is how a $1.6M collections practice ends up with a $650K offer.

Panel Size and Composition

The industry benchmark for a full-time family physician is roughly 1,800-2,200 active patients. Buyers look at two things: raw panel size and panel composition.

• Panel under 1,500: the practice is thin. Buyers assume attrition or a wind-down.
• 1,800-2,200: the sweet spot for a working practice.
• 2,500+: either you're overcapacity (burnout risk, quality concerns) or you've got efficient extender staff — buyers want to know which.

Composition matters as much as count. A 2,000-patient panel that's 35% Medicare, 40% commercial, 15% pediatric, and 10% self-pay is a buyer's dream — diversified revenue, risk-contract potential on the senior half, and commercial reimbursement rates carrying the middle. A 2,000-patient panel that's 70% Medicaid with 20% Medicare is going to get valued at a meaningful discount because the reimbursement math is brutal.

Full-Spectrum Care Is a Real Premium

This is the factor most family docs underestimate. If you do procedures in-office — joint injections, skin biopsies, endometrial biopsies, colposcopy, vasectomies, IUD insertions, casting — your revenue per visit is 30-60% higher than a practice that refers everything out. Buyers pay more for procedural volume because it's high-margin and hard to replicate.

OB capability is the biggest swing factor of all. A family physician who still delivers babies (increasingly rare in 2026) brings a captive multi-generational patient base. Mom delivers with you, the kids become your patients, the grandparents follow. Practices with active OB add 0.5-1.0x to their EBITDA multiple because the patient loyalty and panel growth are structurally different from a clinic-only practice.

On the other end, if you stopped doing in-office procedures five years ago and refer every laceration to urgent care, you've unknowingly converted your practice into a pure E&M factory, which is the lowest-margin version of family medicine that exists.

The Rural Premium (Yes, It's Real)

Counter to what most sellers assume, rural family practices often get better valuations than suburban or urban ones. I know this sounds backwards — fewer patients, lower payer rates, thinner talent pool — but the buyer dynamics flip the math.

In a rural market, your practice might be the only game in town. The nearest competitor is 35 minutes away. Critical Access Hospitals and regional health systems (Sanford, Avera, Marshfield Clinic, Geisinger in its rural markets) pay premiums to lock in the only primary care in a 30-mile radius because losing it means losing their downstream referral base. I've seen rural family docs get 4.5-5.5x EBITDA from regional health systems while their suburban peers struggle to clear 3.5x against crowded competition.

Rural practices also qualify for loan repayment programs, HRSA designations, and 340B drug pricing in some cases — all of which buyers factor in. If your practice is in a Health Professional Shortage Area (HPSA), make sure the buyer knows.

Who's Actually Buying Family Medicine Practices

The buyer pool in 2026 is narrower than most sellers realize.

• Regional health systems: the most common buyer. They'll either acquire the practice outright or hire you as an employed physician and buy the assets at book value. Expect 3.5-4.5x EBITDA when they actually buy goodwill.
• Privia Health, Aledade, Agilon: value-based care enablers that partner with independent practices. Not always a full acquisition, but a liquidity and upside path.
• Another family physician: rare in 2026. Young FPs overwhelmingly choose employment. When it happens, expect 2-3x SDE, SBA-financed, with the seller carrying a note.
• PE-backed primary care platforms: less interested in pure family medicine than in Medicare-heavy internal medicine. They'll look if you have a senior-heavy panel and in-office procedures.

What Kills Family Medicine Value

Solo and aging. A 62-year-old solo FP with no associate and no extender staff is the single hardest practice to sell in primary care. Buyers know the panel will shrink 20-30% during transition because patients associate care with you, not the practice.

No preventive care billing. Annual wellness visits, Medicare AWV, chronic care management — these are $50-150 per patient per year of high-margin revenue that flow directly to EBITDA. If you're not billing them, you're reporting artificially low earnings.

Heavy Medicaid concentration. Above 50% Medicaid, most buyers simply won't engage. The margin math doesn't work for anyone who has to pay market-rate physician salaries.

Weak documentation. Family medicine is notorious for undercoding. If your average E&M code is 99213 when it should be 99214, you're leaving 15-25% of revenue on the table and your EBITDA looks worse than it actually is. Buyers will notice and adjust upward, but only if you can prove it with a coding audit.

How to Maximize Your Family Medicine Practice Value

Bring back in-office procedures. If you stopped doing skin biopsies and joint injections, restart. Each procedure adds $80-$250 of revenue that takes 10 minutes and flows straight to the bottom line.

Hire a mid-level. An NP or PA handling 40% of visits converts a solo practice into a group and roughly doubles the buyer pool.

Join a value-based enabler. Aledade, Privia, and Agilon aren't right for every practice, but if you have 400+ Medicare patients, getting into an upside-only ACO is the single highest-ROI move you can make 18 months before exit.

Document your add-backs. Separate personal expenses, owner comp, and one-time costs in clean schedules. This is the difference between a defensible adjusted EBITDA story and a buyer doing their own aggressive normalization.

The Bottom Line

Family medicine in 2026 is a specialty in transition. Young physicians don't want to buy practices, so your buyer is almost certainly a health system or a value-based care platform, and both of them value your practice on different metrics than you'd expect. The practices that clear 5x EBITDA aren't the biggest — they're the ones with full-spectrum capability, extender staff, risk-contract exposure, and clean financials. Start the preparation 24 months before you plan to exit, and the math works out much better than walking in cold.